163 related articles for article (PubMed ID: 16515530)
1. Targeting JAK3 and BTK tyrosine kinases with rationally-designed inhibitors.
Vassilev AO; Tibbles HE; DuMez D; Venkatachalam TK; Uckun FM
Curr Drug Targets; 2006 Mar; 7(3):327-43. PubMed ID: 16515530
[TBL] [Abstract][Full Text] [Related]
2. Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl)propenamide].
Mahajan S; Ghosh S; Sudbeck EA; Zheng Y; Downs S; Hupke M; Uckun FM
J Biol Chem; 1999 Apr; 274(14):9587-99. PubMed ID: 10092645
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of inhibiting Bruton's tyrosine kinase, (BTK).
Vassilev AO; Uckun FM
Curr Pharm Des; 2004; 10(15):1757-66. PubMed ID: 15180538
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine kinases as new molecular targets in treatment of inflammatory disorders and leukemia.
Uckun FM; Mao C
Curr Pharm Des; 2004; 10(10):1083-91. PubMed ID: 15078143
[TBL] [Abstract][Full Text] [Related]
5. Bruton's tyrosine kinase as a new therapeutic target.
Uckun FM; Tibbles HE; Vassilev AO
Anticancer Agents Med Chem; 2007 Nov; 7(6):624-32. PubMed ID: 18045057
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel dual Bruton's tyrosine kinase (BTK) and Janus kinase 3 (JAK3) inhibitors as a promising strategy for rheumatoid arthritis.
Liang T; Cen L; Wang J; Cheng M; Guo W; Wang W; Yu C; Zhang H; Wang Y; Hao Z; Jin J; Wu Y; Jiang T; Zhu Q; Xu Y
Bioorg Med Chem; 2023 Dec; 96():117354. PubMed ID: 37944414
[TBL] [Abstract][Full Text] [Related]
7. Discovery of a Novel Class of Covalent Dual Inhibitors Targeting the Protein Kinases BMX and BTK.
Forster M; Liang XJ; Schröder M; Gerstenecker S; Chaikuad A; Knapp S; Laufer S; Gehringer M
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291717
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of boron-containing diphenylpyrimidines as potent BTK and JAK3 dual inhibitors.
Ren J; Shi W; Zhao D; Wang Q; Chang X; He X; Wang X; Gao Y; Lu P; Zhang X; Xu H; Zhang Y
Bioorg Med Chem; 2020 Jan; 28(2):115236. PubMed ID: 31843459
[TBL] [Abstract][Full Text] [Related]
9. Targeting Janus kinase 3 in the treatment of leukemia and inflammatory diseases.
Cetkovic-Cvrlje M; Uckun FM
Arch Immunol Ther Exp (Warsz); 2004; 52(2):69-82. PubMed ID: 15179321
[TBL] [Abstract][Full Text] [Related]
10. Design and synthesis of carbazole carboxamides as promising inhibitors of Bruton's tyrosine kinase (BTK) and Janus kinase 2 (JAK2).
Liu Q; Batt DG; Lippy JS; Surti N; Tebben AJ; Muckelbauer JK; Chen L; An Y; Chang C; Pokross M; Yang Z; Wang H; Burke JR; Carter PH; Tino JA
Bioorg Med Chem Lett; 2015 Oct; 25(19):4265-9. PubMed ID: 26320619
[TBL] [Abstract][Full Text] [Related]
11. Is JAK3 a new drug target for immunomodulation-based therapies?
Papageorgiou AC; Wikman LE
Trends Pharmacol Sci; 2004 Nov; 25(11):558-62. PubMed ID: 15491777
[TBL] [Abstract][Full Text] [Related]
12. The anti-leukemic Bruton's tyrosine kinase inhibitor alpha-cyano-beta-hydroxy-beta-methyl-N-(2,5-dibromophenyl) propenamide (LFM-A13) prevents fatal thromboembolism.
Uckun FM; Vassilev A; Bartell S; Zheng Y; Mahajan S; Tibbles HE
Leuk Lymphoma; 2003 Sep; 44(9):1569-77. PubMed ID: 14565661
[TBL] [Abstract][Full Text] [Related]
13. JAK3 inhibitors in organ transplantation and autoimmune disease.
Xiong Z; Ma A; Chen H
Recent Pat Inflamm Allergy Drug Discov; 2010 Jan; 4(1):75-81. PubMed ID: 19832695
[TBL] [Abstract][Full Text] [Related]
14. Identification of highly potent BTK and JAK3 dual inhibitors with improved activity for the treatment of B-cell lymphoma.
Ge Y; Wang C; Song S; Huang J; Liu Z; Li Y; Meng Q; Zhang J; Yao J; Liu K; Ma X; Sun X
Eur J Med Chem; 2018 Jan; 143():1847-1857. PubMed ID: 29146136
[TBL] [Abstract][Full Text] [Related]
15. Bruton's tyrosine kinase as a molecular target in treatment of leukemias and lymphomas as well as inflammatory disorders and autoimmunity.
Uckun FM; Qazi S
Expert Opin Ther Pat; 2010 Nov; 20(11):1457-70. PubMed ID: 20831363
[TBL] [Abstract][Full Text] [Related]
16. Clinical potential of targeting Bruton's tyrosine kinase.
Uckun FM
Int Rev Immunol; 2008; 27(1-2):43-69. PubMed ID: 18300055
[TBL] [Abstract][Full Text] [Related]
17. TR-FRET binding assay targeting unactivated form of Bruton's tyrosine kinase.
Asami T; Kawahata W; Sawa M
Bioorg Med Chem Lett; 2015; 25(10):2033-6. PubMed ID: 25872980
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic potential of Janus kinase 3 (JAK3) inhibitors.
Cetkovic-Cvrlje M; Tibbles HE
Curr Pharm Des; 2004; 10(15):1767-84. PubMed ID: 15180539
[TBL] [Abstract][Full Text] [Related]
19. Terreic acid, a quinone epoxide inhibitor of Bruton's tyrosine kinase.
Kawakami Y; Hartman SE; Kinoshita E; Suzuki H; Kitaura J; Yao L; Inagaki N; Franco A; Hata D; Maeda-Yamamoto M; Fukamachi H; Nagai H; Kawakami T
Proc Natl Acad Sci U S A; 1999 Mar; 96(5):2227-32. PubMed ID: 10051623
[TBL] [Abstract][Full Text] [Related]
20. Dual targeting of Bruton's tyrosine kinase and Janus kinase 3 with rationally designed inhibitors prevents graft-versus-host disease (GVHD) in a murine allogeneic bone marrow transplantation model.
Cetkovic-Cvrlje M; Uckun FM
Br J Haematol; 2004 Sep; 126(6):821-7. PubMed ID: 15352986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
